Нет интернет-соединения — показывается сохранённая версия страницы.

Alnylam Pharmaceu…

USUSD
← К скринеру
US:ALNYLSE:0HD2

Alnylam Pharmaceuticals Inc (US:ALNY) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.

О компании

Сайт
alnylam.com
Взаимодействие с инвесторами
investors.alnylam.com/press-releases
Сектор
Health Care · Biotechnology: Pharmaceutical Preparations
Штаб-квартира
Cambridge, United States
Генеральный директор
Dr. Yvonne L. Greenstreet M.B.A., M.D.
Сотрудники
2 500
Основана
2002
Акций в обращении
133.81 млн на 2026-07-24
Свободное обращение
133.24 млн
Рыночная капитализация
34.17 млрд USD
Инсайдеры
0.18%
Институциональные инвесторы
101.67%
Отрасль (SIC)
Pharmaceutical Preparations
ISIN
US02043Q1076
LEI
529900S3ZI14OWRJII50
Описание

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Биржи и тикеры

БиржаТикерВалютаЦенаТип
US USA StocksALNY основнойUSD224.53 +0.05%обыкновенные акции
LSE London Stock Exchange0HD2 IOBUSD254.589 +0.00%обыкновенные акции

Цена за 3 месяца

день роста день падения экс-дата дивиденда дата выплатыНаведите / коснитесь дня — цены открытия, закрытия, максимальная и минимальная

Дивиденды

Выплаты дивидендов не обнаружены (проверено 09.10.2026). Компания, вероятно, не выплачивает дивиденды.

Новости этой недели

За последнюю неделю новостей нет. Последняя новость: 29.09.2026.

реклама

Крупнейшие держатели

ДержательДоляАкцииДата отчета
FMR, LLC11.23%15.02 млн2026-06-30
Capital World Investors8.33%11.14 млн2026-06-30
Blackrock Inc.8.15%10.91 млн2026-06-30
Capital Research Global…7.29%9.75 млн2026-06-30
Growth Fund of America5.7%7.62 млн2026-06-30
Vanguard Portfolio Manag…4.89%6.54 млн2026-06-30
Vanguard Capital Managem…4.51%6.03 млн2026-06-30
T. Rowe Price Investment…4.22%5.64 млн2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%4.24 млн2026-06-30
Amcap Fund3.07%4.1 млн2026-06-30
Invesco Ltd.2.81%3.75 млн2026-06-30
State Street Corporation2.66%3.56 млн2026-06-30
VANGUARD INDEX FUNDS-Van…2.16%2.89 млн2026-06-30
Invesco QQQ Trust, Serie…2.15%2.87 млн2026-08-31
JPMORGAN CHASE & CO2%2.68 млн2026-06-30
Fidelity Securities Fund…1.6%2.14 млн2026-07-31
T. ROWE PRICE CAPITAL AP…1.52%2.03 млн2026-06-30
VANGUARD SPECIALIZED FUN…1.25%1.67 млн2026-04-30
VANGUARD INDEX FUNDS-Van…1.21%1.62 млн2026-06-30
Investment Co of America1.21%1.61 млн2026-06-30
SHARP PHILLIP A (Directo…≈0.2%266 8992025-01-23
GREENSTREET YVONNE L (Ch…≈0.07%96 2092026-09-18
POULTON JEFFREY V (Chief…≈0.05%61 8622026-03-04
TANGULER TOLGA (Officer)≈0.03%34 2972026-03-04
PYOTT DAVID E I (Directo…≈0.02%29 4822026-06-01
SCHULMAN AMY W. (Directo…≈0.02%24 0492026-05-20
FITZGERALD KEVIN JOSEPH…≈0.02%21 1062026-03-05
BONNEY MICHAEL W (Direct…≈0.02%20 8042025-08-18
GARG PUSHKAL (Officer)≈0.01%19 3742026-03-05
SUPRAN BRYAN (Officer)≈0.01%14 5652026-03-02